Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK.

Objectives: Budesonide/formoterol (BF) Spiromax is an inhaled corticosteroid/long-acting β-agonist fixed-dose combination (FDC) inhaler, designed to minimise common inhaler errors and provide reliable and consistent dose delivery in asthma and chronic obstructive pulmonary disease (COPD). We evaluated non-inferiority of BF Spiromax after changing from another FDC inhaler, compared with continuing the original inhaler.

Methods: Patients with asthma and/or COPD who switched to BF Spiromax were matched (1:3) with non-switchers.